Valuation: Apellis Pharmaceuticals, Inc.

Market Cap 5.25B 4.71B 4.35B 3.94B 7.35B 500B 7.45B 52.03B 20.73B 262B 19.71B 19.29B 828B P/E 2024
-20x
P/E 2025 146x
Enterprise Value 5.26B 4.71B 4.35B 3.95B 7.36B 501B 7.46B 52.09B 20.75B 262B 19.73B 19.32B 829B EV / Sales 2024
5.15x
EV / Sales 2025 3.17x
Free-Float
88.57%
Yield 2024 *
-
Yield 2025 -

Last Transcript: Apellis Pharmaceuticals, Inc.

1 day-0.07%
6 months+0.10%
Current year+63.34%
Current year 16.83
Extreme 16.83
41.14
1 year 16.83
Extreme 16.83
41.14
3 years 16.1
Extreme 16.1
73.8
5 years 16.1
Extreme 16.1
94.75
10 years 11.45
Extreme 11.45
94.75
Manager TitleAgeSince
Director of Finance/CFO 55 2017-09-30
Chief Tech/Sci/R&D Officer 59 2023-01-02
Corporate Secretary - -
Date Insider Type Main position Quantity % Market Cap. Importance
5/14/26 Tender

Director

-63,416 0.0496%
5/14/26 Tender

Director

-297,904 0.2330%
5/14/26 Tender

General Counsel

-928,388 0.7263%
Change 5-day change 1-year change 3-year change Capi.($)
-0.07%-.--%+36.54%-13.69% 5.25B
+0.50%+1.38%+57.09%+129.96% 1,143B
+0.86%+5.14%+45.00%+86.15% 647B
-0.14%+0.42%+25.69%+105.85% 506B
-0.05%+2.28%+49.14%+67.74% 384B
-0.63%-5.97%+61.93%+37.06% 350B
+0.34%+2.15%+25.26%+54.27% 293B
-0.45%+1.16%+1.74%+26.08% 265B
+0.87%+3.08%+54.69%+72.74% 242B
+0.08%+3.67%+35.05%+107.78% 197B
Average +0.30%+0.74%+39.21%+67.39% 403.28B
Weighted average by Cap. +0.40%+0.71%+43.67%+88.88%

Financials

2024 2025
Net sales 781M 700M 647M 586M 1.09B 74.39B 1.11B 7.74B 3.08B 38.94B 2.93B 2.87B 123B 1B 900M 831M 753M 1.4B 95.57B 1.42B 9.94B 3.96B 50.02B 3.77B 3.69B 158B
Net income -198M -177M -164M -148M -277M -18.84B -281M -1.96B -781M -9.86B -742M -727M -31.21B 22.39M 20.06M 18.53M 16.8M 31.31M 2.13B 31.74M 222M 88.35M 1.12B 83.99M 82.23M 3.53B
Net Debt 53.65M 48.08M 44.39M 40.25M 75.03M 5.11B 76.06M 531M 212M 2.67B 201M 197M 8.46B 6.57M 5.89M 5.44M 4.93M 9.19M 626M 9.32M 65.12M 25.94M 328M 24.66M 24.15M 1.04B
Projected Income Statement - Annual - Apellis Pharmaceuticals, Inc.
Logo Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.
Employees
736
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Apellis Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. APLS Stock